Status:

COMPLETED

Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)

Lead Sponsor:

Arrowhead Pharmaceuticals

Conditions:

Hypertriglyceridemia

Familial Chylomicronemia

Eligibility:

All Genders

18-70 years

Phase:

PHASE1

Brief Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple doses of ARO-APOC3 in healthy adult volunteers and in patients with sev...

Eligibility Criteria

Inclusion

  • Women of childbearing potential must have a negative pregnancy test, cannot be breastfeeding and must be willing to use contraception
  • Willing to provide written informed consent and to comply with study requirements
  • Normal electrocardiogram (ECG) at screening
  • Hypertriglyceridemic patients must have a history of fasting serum triglycerides of at least 300 mg/dL (3.38 mmol/L) at screening or verifiable diagnosis of FCS

Exclusion

  • Clinically significant health concerns
  • Regular use of alcohol within one month prior to Screening
  • Use of an investigational agent or device within 30 days prior to dosing or current participation in an investigational study
  • Recent use of illicit drugs
  • Use of more than two tobacco/nicotine containing or cannabis products per month within 6 months prior to drug administration (applicable only to Normal Healthy Volunteers)
  • Note: additional inclusion/exclusion criteria may apply, per protocol

Key Trial Info

Start Date :

March 8 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 11 2021

Estimated Enrollment :

112 Patients enrolled

Trial Details

Trial ID

NCT03783377

Start Date

March 8 2019

End Date

February 11 2021

Last Update

December 24 2025

Active Locations (10)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (10 locations)

1

Research Site 2

Camperdown, New South Wales, Australia, 2050

2

Research Site 5

Sippy Downs, Queensland, Australia

3

Research Site 3

Adelaide, South Australia, Australia, 5000

4

Research Site 4

Perth, Washington, Australia, 6009